Literature DB >> 21705418

Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis.

Jessica L Zambonin1, Chao Zhao, Nobuhiko Ohno, Graham R Campbell, Sarah Engeham, Iryna Ziabreva, Nadine Schwarz, Sok Ee Lee, Josa M Frischer, Doug M Turnbull, Bruce D Trapp, Hans Lassmann, Robin J M Franklin, Don J Mahad.   

Abstract

Mitochondrial content within axons increases following demyelination in the central nervous system, presumably as a response to the changes in energy needs of axons imposed by redistribution of sodium channels. Myelin sheaths can be restored in demyelinated axons and remyelination in some multiple sclerosis lesions is extensive, while in others it is incomplete or absent. The effects of remyelination on axonal mitochondrial content in multiple sclerosis, particularly whether remyelination completely reverses the mitochondrial changes that follow demyelination, are currently unknown. In this study, we analysed axonal mitochondria within demyelinated, remyelinated and myelinated axons in post-mortem tissue from patients with multiple sclerosis and controls, as well as in experimental models of demyelination and remyelination, in vivo and in vitro. Immunofluorescent labelling of mitochondria (porin, a voltage-dependent anion channel expressed on all mitochondria) and axons (neurofilament), and ultrastructural imaging showed that in both multiple sclerosis and experimental demyelination, mitochondrial content within remyelinated axons was significantly less than in acutely and chronically demyelinated axons but more numerous than in myelinated axons. The greater mitochondrial content within remyelinated, compared with myelinated, axons was due to an increase in density of porin elements whereas increase in size accounted for the change observed in demyelinated axons. The increase in mitochondrial content in remyelinated axons was associated with an increase in mitochondrial respiratory chain complex IV activity. In vitro studies showed a significant increase in the number of stationary mitochondria in remyelinated compared with myelinated and demyelinated axons. The number of mobile mitochondria in remyelinated axons did not significantly differ from myelinated axons, although significantly greater than in demyelinated axons. Our neuropathological data and findings in experimental demyelination and remyelination in vivo and in vitro are consistent with a partial amelioration of the supposed increase in energy demand of demyelinated axons by remyelination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21705418      PMCID: PMC3122369          DOI: 10.1093/brain/awr110

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  45 in total

1.  Axonal mitochondrial transport and potential are correlated.

Authors:  Kyle E Miller; Michael P Sheetz
Journal:  J Cell Sci       Date:  2004-05-18       Impact factor: 5.285

2.  Identification and investigation of mitochondria lacking cytochrome c oxidase activity in axons.

Authors:  J Zambonin; S Engeham; G R Campbell; I Ziabreva; N E Beadle; R W Taylor; D J Mahad
Journal:  J Neurosci Methods       Date:  2010-07-24       Impact factor: 2.390

3.  Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination.

Authors:  S A Shields; J M Gilson; W F Blakemore; R J Franklin
Journal:  Glia       Date:  1999-10       Impact factor: 7.452

4.  Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis.

Authors:  I Coman; M S Aigrot; D Seilhean; R Reynolds; J A Girault; B Zalc; C Lubetzki
Journal:  Brain       Date:  2006-06-09       Impact factor: 13.501

5.  Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis.

Authors:  H E Andrews; P P Nichols; D Bates; D M Turnbull
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

6.  Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger.

Authors:  Matthew J Craner; Jia Newcombe; Joel A Black; Caroline Hartle; M Louise Cuzner; Stephen G Waxman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

7.  Remyelination in multiple sclerosis.

Authors:  J W Prineas; F Connell
Journal:  Ann Neurol       Date:  1979-01       Impact factor: 10.422

8.  Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system.

Authors:  Jacques Penderis; Simon A Shields; Robin J M Franklin
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

9.  The restoration of conduction by central remyelination.

Authors:  K J Smith; W F Blakemore; W I McDonald
Journal:  Brain       Date:  1981-06       Impact factor: 13.501

10.  Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis.

Authors:  Graham R Campbell; Iryna Ziabreva; Amy K Reeve; Kim J Krishnan; Richard Reynolds; Owen Howell; Hans Lassmann; Doug M Turnbull; Don J Mahad
Journal:  Ann Neurol       Date:  2010-11-08       Impact factor: 10.422

View more
  47 in total

Review 1.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

2.  Deletion of mitochondrial anchoring protects dysmyelinating shiverer: implications for progressive MS.

Authors:  Dinesh C Joshi; Chuan-Li Zhang; Tien-Min Lin; Anchal Gusain; Melissa G Harris; Esther Tree; Yewin Yin; Connie Wu; Zu-Hang Sheng; Robert J Dempsey; Zsuzsanna Fabry; Shing Yan Chiu
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

Review 3.  Mechanisms for the maintenance and regulation of axonal energy supply.

Authors:  Kelly Anne Chamberlain; Zu-Hang Sheng
Journal:  J Neurosci Res       Date:  2019-03-18       Impact factor: 4.164

Review 4.  SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.

Authors:  Vamshi K C Nimmagadda; Tapas K Makar; Krish Chandrasekaran; Avinash Rao Sagi; Jayanta Ray; James W Russell; Christopher T Bever
Journal:  J Neuroimmunol       Date:  2016-07-17       Impact factor: 3.478

Review 5.  Neurodegeneration in Progressive Multiple Sclerosis.

Authors:  Graham Campbell; Don Mahad
Journal:  Cold Spring Harb Perspect Med       Date:  2018-10-01       Impact factor: 6.915

6.  Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis.

Authors:  Iraj Ragerdi Kashani; Zahra Rajabi; Mohammad Akbari; Gholamreza Hassanzadeh; Alireza Mohseni; Mohammadtaha Kouchakinejad Eramsadati; Kheirollah Rafiee; Cordian Beyer; Markus Kipp; Adib Zendedel
Journal:  Exp Brain Res       Date:  2014-05-06       Impact factor: 1.972

7.  Interactions between mitochondria and endoplasmic reticulum in demyelinated axons.

Authors:  Truc Quynh Thai; Huy Bang Nguyen; Yang Sui; Kazuhiro Ikenaka; Toshiyuki Oda; Nobuhiko Ohno
Journal:  Med Mol Morphol       Date:  2018-11-17       Impact factor: 2.309

Review 8.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

9.  Promoting return of function in multiple sclerosis: An integrated approach.

Authors:  Mar Gacias; Patrizia Casaccia
Journal:  Mult Scler Relat Disord       Date:  2013-10-01       Impact factor: 4.339

Review 10.  Mitochondrial complex enzyme activities and cytochrome C expression changes in multiple sclerosis.

Authors:  Pedro Iñarrea; Raquel Alarcia; María A Alava; José L Capablo; Alvaro Casanova; Cristina Iñiguez; María Iturralde; Pilar Larrodé; Jesús Martín; Enrique Mostacero; José R Ara
Journal:  Mol Neurobiol       Date:  2013-06-13       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.